Andre Braugher’s Cancer Dx; Malignancies Rising in Younger Adults; Negative Trials

Actor Andre Braugher, who passed away this week at the age of 61, was diagnosed with lung cancer a few months ago, according to his publicist. (New York Times)

With more and more young people receiving cancer diagnoses, the National Cancer Institute and Cancer Research U.K. have made finding out why a top priority. (New Scientist)

With the decline in smoking prevalence, an increasing proportion of lung cancer deaths are unrelated to smoking. (Journal of the National Cancer Institute)

Meanwhile, Kate Micucci, who featured in the television series “Big Bang Theory,” announced she underwent recent surgery for lung cancer — an unexpected diagnosis “because I’ve never smoked a cigarette in my life.” (CNN)

Merck and Eisai announced that a phase III trial evaluating first-line pembrolizumab (Keytruda) plus lenvatinib (Lenvima) in advanced or recurrent endometrial cancer patients, whose disease is either mismatch repair-deficient or mismatch repair-proficient but not microsatellite instability-high, failed to improve overall and progression-free survival.

Merck also announced that the KEYLYNK-008 trial evaluating pembrolizumab plus olaparib (Lynparza) for patients with metastatic squamous non-small cell lung cancer was stopped for futility.

Prediabetes treatment might reduce the risk of atherosclerotic cardiovascular disease or kidney disease in childhood cancer survivors. (Journal of Clinical Oncology)

Candel Therapeutics announced that the FDA granted fast track designation to CAN-2409 — a novel viral oncolytic immunotherapy — plus antiviral valacyclovir for the treatment of pancreatic cancer.

The FDA approved bevacizumab-tnjn (Avzivi) as a biosimilar version of Avastin, Bio-Thera Solutions announced.

A biomedical engineer developed a process that uses a 3D bioprinter to fabricate customized breast prosthetics for cancer survivors that are lightweight, flexible, and porous. (University of Connecticut)

Please enable JavaScript to view the

comments powered by Disqus.